Advertisement
Goodbye job applications, hello dream career
Seize control of your career and design the future you deserve with LW career

Imricor Medical Systems makes ASX debut

Johnson Winter & Slattery has advised US-headquartered Imricor Medical Systems, Inc (Imricor) on its initial public offering of CHESS Depositary Interests (CDIs) and listing on the Australian Securities Exchange (ASX).

user iconEmma Musgrave 06 September 2019 Big Law
James Rozsa
expand image

Firm: Johnson Winter & Slattery (Imricor Medical Systems)

Deal: Imricor was advised on its IPO of CHESS Depositary Interests (CDIs) and listing on the ASX. JWS also advised the company on a pre-IPO round of financing.

Value: Under the pre-IPO round and then the IPO and a concurrent placement, Imricor raised a total of $29.7 million. The IPO itself raised $12.1 million and involved the issue of CDIs to Australian institutional and retail investors and to institutional investors in certain overseas jurisdictions. The IPO was priced at $0.83 per CDI and closed trading on its first day at $1.45, an increase of 75 per cent, a statement from JWS said.

Area: Corporate

Key players: The JWS team was led by partners James Rozsa and Clare Brown, supported by senior associates Scott Cummins and Melanie Hemers, and associates Jack Culbertson and Rebecca Proudman.

Deal significance: Imricor is a US-based company, focused on designing, manufacturing and selling medical devices that can be used to carry out cardiac ablation procedures for the treatment of heart arrhythmias.

Imricor’s primary product offering, the Vision-MR Ablation Catheter, is designed to work under real-time MRI guidance, with the intent of enabling higher procedure  success rates along with a faster and safer treatment compared to conventional procedures using x-ray-guided catheters, the statement from JWS explained.

“The funds generated from this transaction will be used to enable the commercial launch of Imricor’s product portfolio allowing the company to enter the markets in Europe, Australia and the US, Mr Rozsa said.

"With this investment, Imricor will be one of the first companies to give patients with abnormal heart rates commercially viable MRI-compatible products.”

Emma Musgrave

Emma Musgrave

Emma Musgrave (née Ryan) is the managing editor, professional services at Momentum Media.

Emma has worked for Momentum Media since 2015, including five years spent as the editor of the company's legal brand - Lawyers Weekly. Throughout her time at Momentum, she has been responsible for breaking some of the biggest stories in corporate Australia. In addition, she has produced exclusive multimedia and event content related to the company's respective brands and audiences. 

Prior to joining Momentum Media, Emma worked in breakfast radio, delivering news to the Central West region of NSW, before taking on a radio journalist role at Southern Cross Austereo, based in Townsville, North Queensland.

She holds a Bachelor of Communications (Journalism) degree from Charles Sturt University. 

Email Emma on: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Tags
You need to be a member to post comments. Become a member for free today!